FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

William Fogler

Research Profile

Living Beings

Chemicals & Drugs

Procedures

Neoplasm Transplantation

Anatomy

Physiology

Cell Movement

Disorders

Experimental Melanomas

Co-author Network

Publications

TOP 3
Matthew H Kulke; Emily K Bergsland; David P Ryan; Peter C Enzinger; Thomas J Lynch; Andrew X Zhu; Jeffrey A Meyerhardt; John V Heymach; William E Fogler; Carolyn Sidor; Ann Michelini; Kate Kinsella; Alan P Venook; Charlie S Fuchs
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
Stacy M Plum; William E Fogler
Anti-angiogenic vaccines as a treatment modality for cancer.
Stacy M Plum; Hong A Vu; Bobby Mercer; William E Fogler; Anne H Fortier
Generation of a specific immunological response to FGF-2 does not affect wound healing or reproduction.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of William Fogler (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: Matthew H Kulke; Emily K Bergsland; David P Ryan; Peter C Enzinger; Thomas J Lynch; Andrew X Zhu; Jeffrey A Meyerhardt; John V Heymach; William E Fogler; Carolyn Sidor; Ann Michelini; Kate Kinsella; Alan P Venook; Charlie S Fuchs
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(22):3555-61.
2004: Stacy M Plum; William E Fogler
Anti-angiogenic vaccines as a treatment modality for cancer.
Current opinion in investigational drugs (London, England : 2000) 2004;5(12):1243-6.
2004: Stacy M Plum; Hong A Vu; Bobby Mercer; William E Fogler; Anne H Fortier
Generation of a specific immunological response to FGF-2 does not affect wound healing or reproduction.
Immunopharmacology and immunotoxicology 2004;26(1):29-41.
2003: Stacy M Plum; Arthur D Hanson; Kirk M Volker; Hong A Vu; B Kim Lee Sim; William E Fogler; Anne H Fortier
Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(12):4619-26.
2003: Laurens V Beerepoot; Els O Witteveen; Gerard Groenewegen; William E Fogler; B Kim Lee Sim; Carolyn Sidor; Bernard A Zonnenberg; Franz Schramel; Martijn F B G Gebbink; Emile E Voest
Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(11):4025-33.
2002: Joseph P Eder; Jeffrey G Supko; jeffrey clark; Thomas A Puchalski; Rocio Garcia-Carbonero; David P Ryan; Larry N Shulman; Joann Proper; Moira Kirvan; Barbara Rattner; Susan Connors; Mary T Keogan; Milos J Janicek; William E Fogler; Lowell E Schnipper; Nancy Kinchla; Carolyn Sidor; Eric Phillips; Judah Folkman; Donald Kufe
Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(18):3772-84.
2001: Oliver Kisker; Christian M Becker; D Prox; Michael Fannon; Robert J D'Amato; Evelyn Flynn; William E Fogler; B Kim Lee Sim; E N Allred; Steven R Pirie-Shepherd; Judah Folkman
Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model.
Cancer research 2001;61(20):7669-74.
2000: Stacy M Plum; John Holaday; A Ruiz; John Madsen; William E Fogler; Anne H Fortier
Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development.
Vaccine 2000;19(9-10):1294-303.
1999: Nicholas J MacDonald; A C Murad; William E Fogler; Y Lu; B Kim Lee Sim
The tumor-suppressing activity of angiostatin protein resides within kringles 1 to 3.
Biochemical and biophysical research communications 1999;264(2):469-77.
1999: M Watanabe; Robert G Fenton; JON WIGGINTON; K L McCormick; Kirk M Volker; William E Fogler; P G Roessler; Robert Wiltrout
Intradermal delivery of IL-12 naked DNA induces systemic NK cell activation and Th1 response in vivo that is independent of endogenous IL-12 production.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(4):1943-50.
1999: Jamshed H Shah; Glenn M Swartz; Adonia Papathanassiu; Anthony M Treston; William E Fogler; John Madsen; Shawn Green
Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis.
Journal of medicinal chemistry 1999;42(16):3014-7.
1999: B Kim Lee Sim; William E Fogler; X H Zhou; H Liang; John Madsen; K Luu; M S O'Reilly; J E Tomaszewski; Anne H Fortier
Zinc ligand-disrupted recombinant human Endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile.
Angiogenesis 1999;3(1):41-51.
1998: William E Fogler; Kirk M Volker; M Watanabe; JON WIGGINTON; P Roessler; MJ Brunda; John R Ortaldo; Robert Wiltrout
Recruitment of hepatic NK cells by IL-12 is dependent on IFN-gamma and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(11):6014-21.
1997: Llewellyn H Mason; P Gosselin; Stephen K Anderson; William E Fogler; John R Ortaldo; Daniel W McVicar
Differential tyrosine phosphorylation of inhibitory versus activating Ly-49 receptor proteins and their recruitment of SHP-1 phosphatase.
Journal of immunology (Baltimore, Md. : 1950) 1997;159(9):4187-96.
1997: M Watanabe; K L McCormick; Kirk M Volker; John R Ortaldo; JON WIGGINTON; MJ Brunda; Robert Wiltrout; William E Fogler
Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis.
The American journal of pathology 1997;150(5):1869-80.
1996: William E Fogler; Kirk M Volker; K L McCormick; M Watanabe; John R Ortaldo; Robert Wiltrout
NK cell infiltration into lung, liver, and subcutaneous B16 melanoma is mediated by VCAM-1/VLA-4 interaction.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(12):4707-14.
1996: Susanna M Rybak; J W Pearson; William E Fogler; Kirk M Volker; S E Spence; Dianne L Newton; Stanislaw M Mikulski; Wojciech Ardelt; C W Riggs; H F Kung; Dan Longo
Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease.
Journal of the National Cancer Institute 1996;88(11):747-53.
1995: William E Fogler; J W Pearson; Kirk M Volker; K Ariyoshi; H Watabe; C W Riggs; Robert Wiltrout; Dan Longo
Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody.
Journal of the National Cancer Institute 1995;87(2):94-104.
1994: A M Pilaro; D D Taub; K L McCormick; H M Williams; Thomas J Sayers; William E Fogler; Robert Wiltrout
TNF-alpha is a principal cytokine involved in the recruitment of NK cells to liver parenchyma.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(1):333-42.
1993: J W Pearson; William E Fogler; Kirk M Volker; C W Riggs; E Gruys; E S Groves; Robert Wiltrout; Dan Longo
Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
Journal of the National Cancer Institute 1993;85(11):907-12.
1991: J W Pearson; William E Fogler; Kirk M Volker; N Usui; S K Goldenberg; E Gruys; C W Riggs; Kristin L Komschlies; Robert Wiltrout; T Tsuruo
Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody.
Journal of the National Cancer Institute 1991;83(19):1386-91.
1990: J W Pearson; E Hedrick; William E Fogler; R L Bull; Douglass K Ferris; C W Riggs; Robert Wiltrout; G Sivam; AC Morgan; E Groves
Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant alpha-interferon.
Cancer research 1990;50(19):6379-88.
1989: M J Gilbreath; William E Fogler; G M Swartz; Carl R Alving; M S Meltzer
Inhibition of interferon gamma-induced macrophage microbicidal activity against Leishmania major by liposomes: inhibition is dependent upon composition of phospholipid headgroups and fatty acids.
International journal of immunopharmacology 1989;11(2):103-10.
1987: William E Fogler; G M Swartz; Carl R Alving
Antibodies to phospholipids and liposomes: binding of antibodies to cells.
Biochimica et biophysica acta 1987;903(2):265-72.